Actualités 2019

« BACK

Pharmacology



Results 1 - 5 of 5.


Pharmacology - 25.11.2019
Missing self triggers NK cell-mediated chronic vascular rejection of solid organ transplants
Publication by CIRI on November 25, 2019. Dogma in transplantation holds that microvascular inflammation (MVI) triggered by recipient's antibody response against alloantigens (antibody-mediated rejection) is the main cause of graft failure. Analysis of a cohort of 129 renal recipients with MVI on graft biopsy shows that, in half of the cases, histological lesions are not mediated by antibodies.

Pharmacology - Life Sciences - 21.11.2019
Get randomly lost, get home sooner
In a multicellular organism, gene expression regulation allows cells to live, divide and ensure their proper physiological role. The molecular nature of this process (e.g. low molecule number, Brownian movements...) involves random variations. Indeed, with the same genetic background, two neighbor cells do not express their genes in the same way.

Life Sciences - Pharmacology - 18.07.2019
New prebiotics: benefits without the downsides?
New prebiotics: benefits without the downsides?
Prebiotics are currently a preferred treatment for certain metabolic disorders, as they can restore the balance of dysfunctional gut microbiota, and improve the body's metabolism. However, these substances have to be used at high doses, which can result in patients experiencing bloating and flatulence.

Innovation - Pharmacology - 22.05.2019
MaaT Pharma expands patent portfolio with three granted patents covering its microbiome restoration biotherapeutic platform
MaaT Pharma expands patent portfolio with three granted patents covering its microbiome restoration biotherapeutic platform
First patents to cover the fundamental processes for accessing the human gut microbiome as biotherapeutics. MaaT Pharma's microbiome sample collection and administration devices receive CE mark for use in collecting and administrating gut-derived samples as biotherapeutics to patients.

Pharmacology - Innovation - 27.02.2019
CEA-Leti Breakthrough Opens Path To New Vaccine for HIV using Lipid-Nanoparticle-Delivery Technology
CEA-Leti Breakthrough Opens Path To New Vaccine for HIV using Lipid-Nanoparticle-Delivery Technology
Lipidots Platform Strengthens Immune Response to Protein That Is Key to HIV Vaccine; Results Presented in Nature Publishing Group's npj Vaccines GRENOBLE, France - Feb. 27, 2019 - Leti, a research institute of CEA Tech, in collaboration with CEA's Fundamental Research Division , has developed a new vaccine approach for HIV based on engineered lipid nanoparticles that deliver p24 - a viral protein that is key to an HIV vaccine- and optimize the CpG adjuvant's effect.

This site uses cookies and analysis tools to improve the usability of the site. More information. |